He discusses the profile of the therapy both as monotherapy and in combination, and compares and contrasts it to competitor data. Plus, the success factors behind Avidity Biosciences, which he co-founded and was recently acquired by Novartis for $12 billion.
View all episodes
By BiotechTV
4.3
66 ratings
He discusses the profile of the therapy both as monotherapy and in combination, and compares and contrasts it to competitor data. Plus, the success factors behind Avidity Biosciences, which he co-founded and was recently acquired by Novartis for $12 billion.
3,374 Listeners
426 Listeners
1,644 Listeners
938 Listeners
125 Listeners
321 Listeners
213 Listeners
6,444 Listeners
61 Listeners
9,855 Listeners
86 Listeners
34 Listeners
19 Listeners
0 Listeners
4 Listeners
2 Listeners
5 Listeners
49 Listeners